Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a neuron-specific protein. At the same time, it is an essential component of the ubiquitin proteasome pathway (UPP) in neurons. The ability of UPP to remove misfolded or damaged proteins in neurons helps ensure normal neuronal function and prevents the accumulation of abnormal proteins. Therefore, maintaining the normal function of UCHL1 during brain disease episodes is critical for disease recovery. Many studies have shown that maintaining or restoring UCHL1 activity is a potential therapeutic strategy for stroke. Therefore, Ace Therapeutics provides comprehensive services to facilitate the development of stroke drugs targeting UCHL1.
Given that studies have shown that maintaining or restoring the activity of UCHL1 is a potential treatment for stroke. Therefore, Ace Therapeutics offers comprehensive services to explore the development of methods to maintain or restore UCHL1 activity for stroke relief.
White matter damage is an important cause of disability after stroke, but there are few stroke treatment options that target white matter damage. Studies have shown that the mutation of the cysteine residue 152 (C152)-reactive lipid-binding site of UCHL1 may reduce stroke damage to gray and white matter and thereby restore motor function after stroke. In view of this, Ace Therapeutics offers comprehensive services to explore the development of stroke therapies based on mutations in C152 of UCHL1.
To explore the impact of mutations in other sites of UCHL1 on stroke, we also provide adequate research services to facilitate the development of stroke therapies regarding UCHL1. If you would like to learn more about our services, please feel free to contact us.
We are committed to accelerating progress in stroke research and drug development.